The Peter Attia Drive

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it's possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary.
If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #84 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
We discuss:
Topics overview [1:15];
Using family history to assess disease risk: why it matters more than genetic testing and how to analyze it effectively [2:30];
Peter's views that differ from conventional medicine: approaches to cardiovascular risk, cancer screening, nutrition, and more [10:30];
Risk tolerance in health decisions: weighing action versus inaction and avoiding low-benefit, high-risk interventions [16:00];
Why cardiovascular disease persists: delayed treatment, insufficient thresholds, and missed opportunities for early intervention [22:00];
Whether someone can be overweight yet metabolically healthy, and how fat distribution influences metabolic risk [26:45];
Strength training with limited time: how to maximize results with intensity and efficiency [30:00];
Designing a sustainable exercise routine: balancing volume, recovery, and enjoyment over time [34:45];
Reducing dementia risk: prioritizing exercise, sleep, and cardiometabolic health based on individual gaps [38:00];
Peter's current skepticism toward NAD-related supplements and what evidence would be needed to change his view [40:45];
Hydration and electrolytes: factors that impact needs and when supplementation might be necessary [43:30]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter explores one of the most foundational topics underlying nearly everything discussed on the podcast: how to think scientifically. Framed as an introspective deep dive, he examines why scientific thinking is inherently difficult for humans, the cognitive biases and tendencies that make it challenging to separate belief from evidence, and why these challenges are even more consequential in today's environment saturated with misinformation. He also offers a framework for improving our ability to evaluate claims, question assumptions, and identify a personal panel of experts, providing listeners with practical tools to become more disciplined and effective thinkers.
We discuss:
Topics to be covered and goals for this episode [2:00];
Scientific thinking: hypotheses, uncertainty, and the process of ruling out explanations [3:45];
How scientific knowledge differs from mathematical proof: useful approximations, evolving evidence, and acting under uncertainty [8:00];
Why scientific thinking is difficult: evolution, social instincts, and the need for deliberate practice [13:30];
Systems and tools designed to correct human bias [18:15];
How to think scientifically pt. 1: Notice when you're feeling certain [20:30];
How to think scientifically pt. 2: Judge the process, not just the conclusion [23:00];
How to think scientifically pt. 3: Notice when identity is shaping your beliefs [28:15];
How to think scientifically pt. 4: Don't confuse criticism with understanding [33:45];
How to think scientifically pt. 5: Outsource your thinking carefully [36:15];
Evaluating who to trust: incentives, consensus, and red flags in scientific credibility [45:15];
Science as a self-correcting system: why updating with evidence is a strength, not a weakness [49:00];
The key principles of scientific thinking, and a practical framework for evaluating claims and improving judgment [50:45]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality.
We discuss:
The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30];
PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30];
The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00];
How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00];
Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00];
Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30];
Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to argue against PSA screening [29:45];
Prostate cancer screening today: improved tools, flawed guidelines, and preventable mortality [33:45];
How finasteride and similar drugs suppress PSA levels and can lead to missed or delayed prostate cancer diagnoses if not properly accounted for [38:00];
The optimistic future of prostate cancer: modern screening advances and the potential to reduce mortality [43:15]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now.
If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #83 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
We discuss:
Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15];
What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30];
A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00];
Peptide case study—SS-31: mechanism of action, approved use in Barth syndrome, and other claimed effects [18:15];
Does the mechanistic rationale for SS-31 translate into measurable benefits? [22:15];
SS-31 continued: safety considerations, gray market risks, the balance of risk versus reward, and why it belongs in bucket #3 [26:00];
Peptide case study—melanotan-II: claimed effects, mechanism of action, safety, and side effects [30:45];
Melanotan-II continued: weighing the potential risks versus benefits and why it belongs in bucket #2 [36:30];
Peptide case study—CJC-1295: growth hormone–stimulating mechanism, claimed effects, and limited human data [40:15];
CJC-1295 continued: dosing uncertainty, risk-reward analysis, lack of long-term safety data, limited approved options, and why it belongs in bucket #2 [49:30];
Peptide case study—BPC 157: uncertain origins, broad claims, and weak mechanistic evidence [57:45];
BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15];
Other popular "gray market" peptides and why they mostly fail when under scrutiny [1:11:15];
How the evidence on peptides compares to rapamycin, and why the lack of data is the biggest concern [1:20:00];
Understanding peptide regulation: FDA approval, supplement oversight, and the risks of gray-market compounds [1:23:00];
Inside the gray market: how peptides are sold, regulated, and why testing cannot guarantee safety [1:26:45];
Limitations of oral peptides, and examples of peptides in bucket #4 [1:31:45];
The future of peptides: real therapeutic potential versus hype in the wellness market [1:35:00]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field's central question: whether improving an aging clock score truly translates into meaningful clinical outcomes.
We discuss:
Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00];
How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00];
The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45];
The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45];
Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15];
The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00];
The DO-HEALTH study results: findings, takeaways, and open questions [27:45];
The DunedinPACNI study: how the model was developed and what it may add to the field [35:00];
The promise and limitations of aging clocks in measuring meaningful biological aging and predicting health outcomes [48:00];
Why aging clocks are not yet reliable as consumer tools and why traditional health metrics still matter most [52:00]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube